VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock.

Several other equities analysts also recently commented on VNRX. StockNews.com began coverage on VolitionRx in a research report on Tuesday. They issued a “sell” rating on the stock. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Price Performance

Shares of VNRX stock opened at $0.63 on Wednesday. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The company’s fifty day moving average price is $0.65 and its 200-day moving average price is $0.66. The company has a market capitalization of $58.38 million, a price-to-earnings ratio of -1.75 and a beta of 1.20.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 358,266 shares of company stock worth $204,212. Company insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC raised its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.